137 related articles for article (PubMed ID: 10288204)
1. FDA asks LyphoMed to recall intravenous solution.
Wagner M
Mod Healthc; 1988 Jul; 18(31):5. PubMed ID: 10288204
[No Abstract] [Full Text] [Related]
2. What you should know about FDA-USP Drug Product Problem Reporting Program.
McGinnis DM
Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
[No Abstract] [Full Text] [Related]
3. Pitfalls of drug manufacturing--an evaluation of 18 months of FDA recalls.
Frediani HA
Bull Parenter Drug Assoc; 1972; 26(4):172-81. PubMed ID: 5067998
[No Abstract] [Full Text] [Related]
4. Regulators scramble to tighten loopholes after heparin debacle.
Jia H
Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
[No Abstract] [Full Text] [Related]
5. Should hospitals report to the FDA?
McNaughton DJ
Healthc Comput Commun; 1987 Oct; 4(10):29. PubMed ID: 10288562
[No Abstract] [Full Text] [Related]
6. Sporicidin responds to the recall of its products.
Healthc Hazard Mater Manage; 1992 Aug; 5(11):8-11. PubMed ID: 10121070
[TBL] [Abstract][Full Text] [Related]
7. The Sporicidin recall.
Healthc Hazard Mater Manage; 1992 Jan; 5(4):9-11. PubMed ID: 10116667
[TBL] [Abstract][Full Text] [Related]
8. Blowing the whistle at the FDA.
Simons J
Fortune; 2005 Jan; 151(2):32. PubMed ID: 15693304
[No Abstract] [Full Text] [Related]
9. Report device failures to the FDA.
JCAH Perspect; 1987; 7(7-8):5-7. PubMed ID: 10289785
[No Abstract] [Full Text] [Related]
10. The FDA animal efficacy rule and biodefense.
Gronvall GK; Trent D; Borio L; Brey R; Nagao L;
Nat Biotechnol; 2007 Oct; 25(10):1084-7. PubMed ID: 17921984
[No Abstract] [Full Text] [Related]
11. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
[TBL] [Abstract][Full Text] [Related]
12. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
13. Policy currents. FDA addresses backlog of generic medication applications.
Consult Pharm; 2006 May; 21(5):419-21. PubMed ID: 16929569
[No Abstract] [Full Text] [Related]
14. Postmarketing surveillance.
Oleen MA
Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
[TBL] [Abstract][Full Text] [Related]
15. A patient-initiated postmarketing surveillance system.
Fisher S; Bryant SG; Solovitz BL; Kluge RM
Psychopharmacol Bull; 1987; 23(3):400-4. PubMed ID: 3432511
[No Abstract] [Full Text] [Related]
16. Mandatory post marketing studies.
Somberg J
Am J Ther; 2007; 14(4):321. PubMed ID: 17667203
[No Abstract] [Full Text] [Related]
17. Rofecoxib, Merck, and the FDA.
Villalba L; Witter J
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
[No Abstract] [Full Text] [Related]
18. FDA notifications. FDA provides more info in response to Viracept recall.
AIDS Alert; 2007 Nov; 22(11):129-31. PubMed ID: 18411458
[No Abstract] [Full Text] [Related]
19. LyphoMed, FDA reach agreement.
Wagner M
Mod Healthc; 1988 May; 18(22):6. PubMed ID: 10287683
[No Abstract] [Full Text] [Related]
20. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Karst KR
Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
[No Abstract] [Full Text] [Related]
[Next] [New Search]
